| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Applied Molecular Transport Inc. | Director | Common Stock | 575,000 | $93,955 | $0.1634 | 27 Aug 2021 | Direct |
| Aktis Oncology, Inc. | Director, 10%+ Owner | Common Stock | 157,387 | 12 Jan 2026 | Indirect | ||
| PROTHENA CORP PUBLIC LTD CO | Director | Stock Option (Right to Buy) | 20,183 | 14 May 2025 | Direct | ||
| Applied Molecular Transport Inc. | Director | Stock Option (Right to Buy) | 14,343 | 18 May 2021 | Direct | ||
| Aktis Oncology, Inc. | Director, 10%+ Owner | Series A Redeemable Convertible Preferred Stock | 0 | 12 Jan 2026 | Indirect | ||
| Aktis Oncology, Inc. | Director, 10%+ Owner | Series B Redeemable Convertible Preferred Stock | 0 | 12 Jan 2026 | Indirect |